secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivos Therapeutics, Inc. (VVOS)
CIK:        0001716166
Form:       8-K
Filed at:   2026-01-16T23:59:59+00:00
Accession:  0001493152-26-002557
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 2.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivos Therapeutics enters $5.5M convertible note with V-Co, initial $900k funded
--------------------------------------------------------------------------------

- Note up to $5.5M principal (incl. 10% OID) from V-Co Investors 3 LLC, affiliate of existing investor New Seneca Partners.
- Initial $900k funded; additional advances possible until Feb 16, 2026 outside date for proposed equity financing.
- Principal converts dollar-for-dollar into equity instruments of proposed Subsequent Financing; no interest unless default (then 15%).
- Company expects to close $5.5M equity financing by Feb 16, 2026; note supports that process.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716166/000149315226002557/0001493152-26-002557-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716166/000149315226002557/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-002557

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer